Pembrolizumab Versus Docetaxel For Previously Treated, PD-L1-positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial

·2016·DOI

Role in the Field

Abstract

Citations

4,532

Year

2016

PageRank

4.6 / 10

Relative influence (log-scaled)

Pembrolizumab Versus Docetaxel For Previously Treated, PD-L1-positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial | Manumap